Add wos sample results library

2023-09-28 16:46:10 +02:00 · 2023-09-28 16:46:10 +02:00 · 19e409ad85
commit 19e409ad85
parent 6305e61d1f
2173 changed files with 235628 additions and 20 deletions
--- a/02-data/intermediate/wos_sample/415ee4e9942444096508d86cc2aac242-gonzalez-perez-mari/info.yaml
+++ b/02-data/intermediate/wos_sample/415ee4e9942444096508d86cc2aac242-gonzalez-perez-mari/info.yaml
@ -0,0 +1,132 @@
+abstract: 'Despite of the rapid development of the vaccines against the severe
+
+  acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take
+
+  several months to have enough doses and the proper infrastructure to
+
+  vaccinate a good proportion of the world population. In this interim,
+
+  the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the
+
+  pandemic impact in some countries and the BCG vaccine offers significant
+
+  advantages and flexibility in the way clinical vaccines are
+
+  administered. BCG vaccination is a highly cost-effective intervention
+
+  against tuberculosis (TB) and many low-and lower-middle-income countries
+
+  would likely have the infrastructure, and health care personnel
+
+  sufficiently familiar with the conventional TB vaccine to mount
+
+  full-scale efforts to administer novel BCG-based vaccine for COVID-19.
+
+  This suggests the potential for BCG to overcome future barriers to
+
+  vaccine roll-out in the countries where health systems are fragile and
+
+  where the effects of this new coronavirus could be catastrophic. Many
+
+  studies have reported cross-protective effects of the BCG vaccine toward
+
+  non-tuberculosis related diseases. Mechanistically, this
+
+  cross-protective effect of the BCG vaccine can be explained, in part, by
+
+  trained immunity, a recently discovered program of innate immune memory,
+
+  which is characterized by non-permanent epigenetic reprogramming of
+
+  macrophages that leads to increased inflammatory cytokine production and
+
+  consequently potent immune responses. In this review, we summarize
+
+  recent work highlighting the potential use of BCG for the treatment
+
+  respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials.
+
+  In situations where no other specific prophylactic tools are available,
+
+  the BCG vaccine could be used as a potential adjuvant, to decrease
+
+  sickness of SARS-CoV-2 infection and/or to mitigate the effects of
+
+  concurrent respiratory infections.'
+affiliation: 'Ochando, J (Corresponding Author), Inst Salud Carlos III, Dept Immunol,
+  Transplant Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
+
+  Ochando, J (Corresponding Author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York,
+  NY 10029 USA.
+
+  Gonzalez-Perez, Maria; Ochando, Jordi, Inst Salud Carlos III, Dept Immunol, Transplant
+  Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
+
+  Sanchez-Tarjuelo, Rodrigo; Ochando, Jordi, Icahn Sch Med Mt Sinai, Dept Oncol Sci,
+  New York, NY 10029 USA.
+
+  Shor, Boris, Manhattan BioSolut, New York, NY USA.
+
+  Nistal-Villan, Estanislao, Univ San Pablo Ctr Estudios Univ CEU, Fac Farm, Microbiol
+  Sect, Dept Ciencias Farmaceut \& Salud, Madrid, Spain.
+
+  Nistal-Villan, Estanislao, Univ San Pablo CEU, Inst Med Mol Aplicada IMMA, Fac Med,
+  Madrid, Spain.'
+article-number: '632478'
+author: Gonzalez-Perez, Maria and Sanchez-Tarjuelo, Rodrigo and Shor, Boris and Nistal-Villan,
+  Estanislao and Ochando, Jordi
+author-email: Jordi.ochando@mssm.edu.edu
+author_list:
+- family: Gonzalez-Perez
+  given: Maria
+- family: Sanchez-Tarjuelo
+  given: Rodrigo
+- family: Shor
+  given: Boris
+- family: Nistal-Villan
+  given: Estanislao
+- family: Ochando
+  given: Jordi
+da: '2023-09-28'
+doi: 10.3389/fimmu.2021.632478
+files: []
+issn: 1664-3224
+journal: FRONTIERS IN IMMUNOLOGY
+keywords: 'Bacille Calmette-Guerin; SARS-CoV-2; vaccination; trained immunity;
+
+  cross-protection'
+keywords-plus: 'BACILLUS-CALMETTE-GUERIN; RESPIRATORY SYNCYTIAL VIRUS; TRAINED IMMUNITY;
+
+  NONSPECIFIC PROTECTION; GUINEA-BISSAU; RECOMBINANT; INFECTION;
+
+  RESPONSES; EFFICACY; MEMORY'
+language: English
+month: MAR 8
+number-of-cited-references: '68'
+orcid-numbers: 'Ochando, jordi/0000-0001-7037-1681
+
+  Nistal-Villan, Estanislao/0000-0003-2458-8833
+
+  Gonzalez Perez, Maria/0000-0003-0838-4734
+
+  Sanchez Tarjuelo, Rodrigo/0000-0002-3252-2722'
+papis_id: 409cc5f0651b9c4f28972a54ac5577cc
+ref: Gonzalezperez2021bcgvaccine
+researcherid-numbers: 'Ochando, jordi/ABE-2358-2020
+
+  Nistal-Villan, Estanislao/GWM-7994-2022
+
+  Nistal-Villan, Estanislao/C-6122-2015
+
+  '
+tags:
+- review
+times-cited: '43'
+title: 'The BCG Vaccine for COVID-19: First Verdict and Future Directions'
+type: Review
+unique-id: WOS:000630922700001
+usage-count-last-180-days: '0'
+usage-count-since-2013: '4'
+volume: '12'
+web-of-science-categories: Immunology
+year: '2021'